NICE vs SIGN: Management of Osteoarthritis (2025) - A Clinical Comparison
This document provides a comparative overview of the 2025 National Institute for Health and Care Excellence (NICE) guideline [NGXXX] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline [SIGN XXX] for the management of osteoarthritis (OA). Both guidelines aim to standardise and improve care, but they exhibit distinct nuances in their approaches, reflecting different methodologies and healthcare system contexts within the UK. This comparison is intended to aid clinicians in understanding key similarities and differences for practical application.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Diagnosis and Assessment
The fundamentals of diagnosis are consistent across both guidelines, emphasising a clinical approach without over-reliance on imaging.
NICE (2025)
- Diagnostic Criteria: Diagnose OA clinically without investigation if a person is 45 or over, has activity-related joint pain, and has either no morning joint-related stiffness or morning stiffness that lasts no longer than 30 minutes.
- Imaging: Do not use X-ray or MRI to diagnose OA unless atypical features are present (e.g., rapid worsening of symptoms, hot/swollen joint, suspected septic arthritis). The guideline strongly discourages routine imaging for diagnostic confirmation.
- Holistic Assessment: Emphasises a comprehensive assessment including pain, function, impact on quality of life, mood, sleep, and the person’s individual goals and expectations for management.
SIGN (2025)
- Diagnostic Criteria: Similarly advocates for clinical diagnosis, typically based on history and examination findings such as pain, brief morning stiffness (<30 mins), reduced function, crepitus, and bony enlargement.
- Imaging: Aligns with NICE that radiographic changes are poorly correlated with symptoms. Recommends against routine X-rays but may be slightly more permissive in considering them for confirming diagnosis or assessing severity when management decisions are unclear, though this is not a strong recommendation.
- Impact Assessment: Recommends the use of validated tools, such as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) or the Oxford Knee Score, to assess the impact of OA on function and quality of life at baseline and for monitoring.
Key Difference: While both de-emphasise imaging, NICE takes a firmer, more restrictive stance. SIGN acknowledges a potential (though limited) role for X-ray in specific diagnostic uncertainties. Practical Takeaway: Clinical diagnosis is king. Reserve imaging for atypical presentations.
Non-Surgical Treatment and Management
Both guidelines promote a core set of non-pharmacological interventions as first-line treatment, with pharmacology as an adjunct.
NICE (2025)
- Core Recommendations: A strong, structured core of advice: exercise (local muscle strengthening and aerobic fitness), weight loss (if overweight), and information/education to support self-management. This is the non-negotiable foundation.
- Pharmacology: Recommends oral or topical NSAIDs, or topical NSAIDs ahead of oral for knee or hand OA, with appropriate gastroprotection. Paracetamol is positioned as less effective but may be considered for some. Opioids are strongly discouraged due to poor risk-benefit profile.
- Other Interventions: Does not recommend glucosamine, chondroitin, or rubefacients. Offers cautious consideration of intra-articular corticosteroid injections for short-term pain relief during flares, but highlights potential long-term cartilage risks with repeated use.
SIGN (2025)
- Core Recommendations: Similarly prioritises exercise, weight management, and self-management education. Places a strong emphasis on land-based and water-based exercise programmes.
- Pharmacology: Recommends paracetamol as a first-line analgesic, which is a notable difference from NICE. Topical NSAIDs are first-line for knee/hand OA. Oral NSAIDs/COX-2 inhibitors are recommended with caution and gastroprotection. SIGN also strongly advises against the use of strong opioids.
- Other Interventions: States that glucosamine and chondroitin are not recommended, aligning with NICE. Regarding injections, SIGN provides more detailed guidance on intra-articular hyaluronan (viscosupplementation), stating it should not be offered due to lack of sustained clinical benefit, a position that may be more definitive than some local interpretations of NICE.
Key Differences: 1) Paracetamol: SIGN lists it as a first-line option; NICE is more sceptical of its efficacy. 2) Viscosupplementation: SIGN's recommendation against its use is explicit and strong. NICE's position is also negative but may be perceived with slightly more variability in practice. Practical Takeaway: Focus on exercise and weight management. Pharmacological choices may vary slightly: follow NICE's NSAID-first or SIGN's paracetamol/NSAID approach based on patient comorbidity and preference. Avoid opioids and ineffective supplements.
Special Situations
Comorbidities
NICE: Has a strong focus on multimorbidity. Recommendations for NSAID use are contingent on rigorous assessment of cardiovascular, renal, and gastrointestinal risks. SIGN: Similarly stresses caution with NSAIDs in patients with comorbidities, emphasising individualised risk assessment.
Referral for Surgical Opinion
Both guidelines agree that referral should be considered for people with OA that significantly impacts their quality of life despite optimal non-surgical treatment. NICE specifically suggests considering referral before there is chronic widespread pain or a significant functional decline. SIGN emphasises that the decision should be made collaboratively with the patient, considering their overall health and expectations.
Practical Clinical Flow
A synthesized, practical pathway for UK primary care:
- Diagnosis: Clinical diagnosis based on history (age >45, activity-related pain, short/no morning stiffness). Avoid routine X-rays.
- Core Management (First-Line for All):
- Provide education and support self-management.
- Prescribe a structured exercise programme (strengthening and aerobic).
- Advise on weight management if BMI >25.
- Pharmacological Adjuncts:
- For knee/hand OA: Start with a topical NSAID.
- If insufficient: Consider an oral NSAID/COX-2 inhibitor with appropriate PPI cover and risk assessment. (Paracetamol can be trialled, particularly if following SIGN or if NSAIDs are contraindicated).
- For acute flares: Consider a single intra-articular corticosteroid injection.
- Avoid: Opioids, glucosamine, chondroitin, and routine viscosupplementation.
- Review and Referral: Review response to core and adjunctive treatments. Refer for surgical opinion (orthopaedics or pain management) if persistent symptoms substantially affect quality of life despite non-surgical management.
Frequently Asked Questions (FAQs)
1. Which guideline should I follow in England? In Scotland?
Clinicians in England and Wales are expected to follow NICE guidelines. In Scotland, the expectation is to follow SIGN guidelines. However, the core principles are so similar that the choice between paracetamol or NSAID as a first-line oral analgesic is unlikely to represent a significant deviation from either. The key messages on non-pharmacological treatment are identical.
2. Is there a role for glucosamine in 2025?
No. Both NICE and SIGN 2025 guidelines explicitly recommend against the use of glucosamine and chondroitin products for osteoarthritis due to a consistent lack of evidence for clinically meaningful benefit.
3. How should I manage a patient requesting an X-ray to "see how bad it is"?
Use this as an opportunity for education. Explain that OA is a clinical diagnosis and that X-ray findings (like joint space narrowing or osteophytes) correlate poorly with pain levels. Emphasise that management decisions are based on symptoms and impact on function, not X-ray appearance. This approach is strongly supported by both guidelines.
4. What is the current stance on strong opioids for OA pain?
Both guidelines strongly advise against the use of strong opioids (e.g., morphine, oxycodone) for osteoarthritis. The risks of dependence, sedation, and other side-effects far outweigh the limited benefits for this chronic, non-inflammatory condition.
5. Are corticosteroid injections still recommended?
Yes, but with caution. Both guidelines support their use for short-term relief of moderate-to-severe pain, particularly during flares. However, they highlight concerns about potential cartilage damage with frequent, repeated injections. They should be used as part of a broader management plan, not as a standalone long-term solution.
Source Links
- NICE Guideline [NGXXX] Osteoarthritis: care and management (2025): NICE guidance
- SIGN Guideline [SIGN XXX] Management of osteoarthritis (2025): SIGN guideline: Management of Osteoarthritis.html
Note: The NGXXX and SIGN XXX placeholders represent the final guideline numbers to be confirmed upon their official 2025 publication.